PKI-166 hydrochloride  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

库存{{model.attbuying.number}}
包装规格:5mg 10mg 25mg 50mg in glass bottle
产品描述:基本信息 产品编号:P30018 产品名称:PKI-166 hydrochloride CAS: 2230253-82-2   储存条件 粉末 -20℃ 四年 分子式: C20H19ClN4O 分子量 366.84 化学名:  4-[4-[[(1R)-1-Phenylethyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenol hydrochloride   生物活性 产品描述 一种高效、选择性的,具有口服生物活性的EGFR酪氨酸激酶抑制剂,IC50值为0.7nM。 靶点/IC50 IC50: 0.7nM (EGFR tyrosine kinase)   体外研究 PKI-166 hydrochloride (0-0.5μM; 1 hour; pretreatment) inhibits EGFR autophosphorylation in human pancreatic cancer cells. PKI-166 hydrochloride (0.03μM; 6 days) enhances the cytotoxicity mediated by gemcitabine.Western Blot Analysis. Cell Line: L3.6pl cells Concentration: 0.01μM, 0.05μM, 0.5μM Incubation Time: 1hour Result: Inhibited EGFR autophosphorylation in a dose-dependent manner. Cell Cytotoxicity Assay Cell Line: L3.6pl cells Concentration: 0.03μM Incubation Time: 6 days Result: Enhanced the cytotoxicity mediated by gemcitabine.   体内研究 PKI-166 hydrochloride (100mg/kg; p.o.; daily; for 29 days) inhibits of pancreatic cancer growth. Animal Model: Male athymic nude mice with L3.6pl cells xenograft (8-12 weeks) Dosage: 100mg/kg Administration:  Oral administration; daily; for 29 days Result: Significantly decreased median tumor volume.
保存条件:-20℃